Multiple Myeloma Hub

Find out how ocular events associated with belantamab mafodotin in the DREAMM-7 and DREAMM-8 trials were effectively managed with dose modifications, including the impact on patient-reported outcomes. Learn more: loom.ly/Y6bYM8w #MultipleMyeloma #myeloma #MedNews #MedEd

New publication 📝 Updated results from CARTITUDE‑4, published in @TheLancetOncol, demonstrate extended PFS with cilta-cel, corresponding to a 71% reduction in the risk of progression or death vs SoC for Len-refractory #MultipleMyeloma. Learn more: bit.ly/3ZSFZQ9 #myeloma #mmsm #MedNews #MedEd

New publication 📝 Long-term follow-up results from the LINKER-MM1 trial, published in Clinical Lymphoma, Myeloma & Leukemia, show responses to linvoseltamab 200 mg were generally consistent across patient subgroups in relapsed/refractory #MultipleMyeloma, including older patients and those with HRCA. Learn more: bit.ly/3ZSFZQ9 #myeloma #mmsm #MedNews #MedEd

New publication 📝 A new international staging system for AL #amyloidosis (AL‑ISS), published in @JCO_ASCO, incorporated longitudinal strain to existing cardiac biomarkers to refine risk stratification and identify an ultra-poor-risk subgroup (Stage IIIC). Learn more: bit.ly/3ZYt7bp #MedNews #MedEd

📝 Stay ahead of the latest medical news in #MultipleMyeloma! Get the latest trial data, therapy breakthroughs, and expert insights delivered straight to your inbox. Sign up for the Multiple Myeloma Hub newsletter today: bit.ly/3M1msdm #mmsm #MedEd #MedTwitter

🚨NEWS🚨 @US_FDA approves subcutaneous Tec + Dara for the treatment of relapsed/refractory #MultipleMyeloma with ≥1 prior LoT; based on data from the phase III MajesTEC-3 study. Read more: bit.ly/4sAF5nV #myeloma #mmsm #MedEd #MedNews

New publication📝Expert roundtable guidance, published in Clinical Lymphoma, Myeloma & Leukemia, recommends individualizing bridging therapies prior to CAR T-cell therapy for #MultipleMyeloma based on clinical and logistical factors. Learn more: bit.ly/4cmNx5m #myeloma #mmsm #MedNews #MedEd

JOIN NOW! Don’t miss out on our free webinar, taking place on March 5, 10:00 GMT Chair: Rakesh Popat. bit.ly/4rCErWq If you have missed our webinar and would like to be notified of future educational opportunities, please sign up to our newsletter here: bit.ly/3M1msdm

New publication 📝 A post hoc analysis of the phase III PERSEUS trial, published in @BloodPortfolio, shows high baseline CTC (≥0.175%) are independently associated with worse PFS vs low CTC in patients with TE NDMM treated with D-VRd or VRd (HR, 3.56; p < 0.0001). Learn more: bit.ly/4aQnYqW #myeloma #mmsm #MedNews #MedEd

New publication 📝 ASH 2026 guidelines, published in @BloodAdvances, outline 12 key recommendations for the diagnosis of AL #amyloidosis. Learn more: bit.ly/3ZYt7bp #mmsm #MedNews #MedEd

Don’t miss out on our free webinar on March 5, at 10:00 GMT. Chair: Rakesh Popat. Join us live at 10:00 GMT ⬇️ bit.ly/4aJzgyc Discover more about optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. #MultipleMyeloma

This #MyelomaACTIONMonth, we're committed to empowering HCPs with the latest insights to improve #MultipleMyeloma care. 🔬 Latest therapeutics 📊 Clinical trial updates 💡 Expert perspectives Discover more: bit.ly/3NMdVvk #mmsm #MedEd @IMFmyeloma

New publication 📝 Results from a pooled analysis, published in @BloodPortfolio, demonstrated slower MRD clearance in patients with t(11;14)+ NDMM treated with QUAD induction + ASCT, yet comparable sustained MRD− and superior 4-year PFS vs patients with t(11;14)− NDMM. Learn more: bit.ly/4qqvXAO #mmsm #myeloma #MultipleMyeloma #MedNews #MedEd

Don’t forget to join our free webinar on March 5, 2026, at 10:00 GMT to learn more about optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. Chaired by Rakesh Popat. Register here ⬇️ bit.ly/4aJzgyc #MultipleMyeloma

New publication 📝 Translational analyses, published in @NatureMedicine, identified three tumor-intrinsic mechanisms of resistance to GPRC5D in patients with relapsed/refractory #MultipleMyeloma treated with talquetamab. Learn more: bit.ly/3ZSFZQ9 #myeloma #mmsm #MedNews #MedEd

Join us on March 5, 2026, at 10:00 GMT for our free healthcare professional webinar, which includes a patient representative. Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. Chaired by Rakesh Popat, with guest speakers Fredrik Schjesvold, Hang Quach, and Lynn Williams – a patient representative. Register here ⬇️ bit.ly/4aJzgyc This independent educational activity is supported by GSK. All content is developed independently by the faculty. The funder is allowed no influence on the content. #MultipleMyeloma If you have missed our webinar and would like to be notified of future educational opportunities, please sign up to our newsletter here: bit.ly/3M1msdm

New publication📝 CANOVA phase III results, published in @JCO_ASCO show that Vd did not demonstrate superiority vs Pd for PFS in t(11;14) relapsed/refractory #MultipleMyeloma. Learn more: bit.ly/4qqvXAO #myeloma #mmsm #MedNews #MedEd

🚨NEWS🚨 @US_FDA accepts new drug application for iberdomide, an oral cereblon E3 ligase modulator, in combination with daratumumab + dexamethasone (IberDd) for relapsed/refractory #MultipleMyeloma; based on MRD analyses from the phase III EXCALIBER-RRMM study. Read more: bit.ly/3MLMmC2 #myeloma #mmsm #MedEd #MedNews

New publication 📝 ECA analysis of phase III ADMYRE results, published in Annals of Hematology, demonstrated non-inferior OS with plitidepsin + LD‑DXM vs Pom + LD‑DXM in heavily pretreated relapsed/refractory #MultipleMyeloma. Learn more: bit.ly/3ZSFZQ9 #mmsm #myeloma #MedNews #MedEd

💭 Interested in learning more about how we can optimize dosing of BCMA-directed therapies for improved quality of life in multiple myeloma? Join the Multiple Myeloma Hub’s free webinar. Chaired by Rakesh Popat. 📅 March 5 | 10:00 – 11:10 GMT Register here ⬇️ bit.ly/4aJzgyc #MultipleMyeloma

🚨NEWS🚨 @US_FDA clears an Investigational New Drug application for HLX15-SC, a subcutaneous daratumumab biosimilar, allowing evaluation as part of a phase I study in newly diagnosed #MultipleMyeloma. Read more: bit.ly/4aD23mS #myeloma #mmsm #MedEd #MedNews